Kodiak Sciences Inc

Kodiak Sciences, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Kodiak Sciences, Inc. has 62.83M shares outstanding.

As of June 30, 2026, Kodiak Sciences, Inc. maintains a current ratio of 2.49, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Kodiak Sciences, Inc. posted a negative return on equity (ROE) of -368.37, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -94.25, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 120.25, a quick read on workforce productivity versus industry peers.

As of the close on October 14, 2026, Kodiak Sciences, Inc.'s stock has gained approximately 842.35% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Kodiak Sciences, Inc. generated - - in revenue and converted that into -4.23B in net income, yielding earnings per share of -72.97. EBITDA reached -3.86B, while operating income came in at -4.31B.

As of June 30, 2026, Kodiak Sciences, Inc. holds 2.20B in cash and equivalents against 921.73M in total debt, resulting in a net debt position of -2.20B. Total book value stands at 1.07B, with working capital of 1.37B providing operational flexibility.

Kodiak Sciences, Inc. produced -2.77B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -24.41M in capital expenditures, free cash flow totaled -2.79B - equivalent to -48.21 per share.